Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(1 site)
China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Age range
18 Years – 70 Years
Last updated December 2023